Zenas BioPharma CEO & Chairman Discloses 5.16% Stake, Recent $2.4M Share Purchases

summarizeSummary

Zenas BioPharma's CEO and Chairman, Leon O. Moulder, Jr., has disclosed a 5.16% beneficial ownership stake in the company, including recent purchases totaling approximately $2.4 million.

check_boxKey Events

• CEO & Chairman Discloses 5.16% Stake

  Leon O. Moulder, Jr., the company's CEO and Chairman, along with affiliated entities, reported beneficial ownership of 2,806,792 shares, representing 5.16% of the outstanding common stock.

• Recent Open-Market Purchases

  Mr. Moulder purchased 100,000 shares in open-market transactions between January 7-9, 2026, at prices ranging from $15.82 to $16.87, totaling approximately $1.64 million.

• Private Placement Participation

  In October 2025, a trust controlled by Mr. Moulder acquired 36,928 shares at $20.85 per share in a private placement, valued at approximately $770,000.

auto_awesomeAnalysis

This Schedule 13D filing reveals that Leon O. Moulder, Jr., the Chief Executive Officer and Chairman of Zenas BioPharma, along with entities he controls, beneficially owns 5.16% of the company's common stock. The disclosure highlights significant recent purchases, including approximately $770,000 through a trust in an October 2025 private placement at $20.85 per share, and an additional $1.64 million in open-market transactions in early January 2026 at prices ranging from $15.82 to $16.87. These substantial investments by a key executive signal strong confidence in the company's future prospects, especially given the current stock price of $22.50.